Member Info for JungleVIP

UK INVESTOR...

According to estimates by various research houses, the global Generative AI market will be worth anything between $255bn and $826bn by 2030.

Tick up....any minute now

GL. Looking good already this AM

Imo. Patience and faith.

Looking good 👍

UK INVESTOR...

Shares

Updated: 07/12/2024

AI stocks GenIP, Cel AI and Sealand Capital Galaxy all deserve higher valuations

UK Investor Magazine

By

UK Investor Magazine

06/12/2024

The growth prospects for London-listed GenIP, Cel AI, and Sealand Capital Galaxy suggest they deserve higher valuations given the potential size of the Generative AI market in which they operate.

According to estimates by various research houses, the global Generative AI market will be worth anything between $255bn and $826bn by 2030.

- Advertisement -

When you look at GenIP, Cel AI, and Sealand Capital Galaxy’s valuations, it’s clear that current market pricing does not reflect the extent of the opportunity in Generative AI.

Yes, these are higher-risk small-cap companies at the beginning of their growth cycle, but the potential for rapid top-line growth is underappreciated.

We delve into each company’s operations and the specific real-world problems it uses Generative AI to solve for its clients.

GenIP

Revenue-generating GenIP has already achieved material orders for its Generative AI analytics services and offers investors the potential for exponential growth.

- Advertisement -

After developing and implementing its own Generative AI models, GenIP has demonstrated a clear demand for its new Generative AI-enhanced services, which are designed to assist in commercialising new technology.

The company plays a vital role in assisting research institutions’ Technology Transfer Offices (TTOs) in commercialising new technology discoveries and providing the leadership to take innovations to market.

GenIP is ‘laser-focused on building’ on its early momentum and is on the verge of launching a marketing campaign that should accelerate traction with its target market of universities, investment funds and corporate research units.

Since its IPO in October, the company has announced a doubling in the pace of orders from a Fortune 100 technology company and the penetration of global markets with new customers in Saudi Arabia. GenIP currently works with around 40 research institutions and plans to roll its services out to potentially 1000s more.

The company offers two core services: Invention Evaluator, which provides Technology Transfer Offices with detailed analytical reports to help them assess the commercial prospects of new technology discoveries, and Vortechs, an executive search service enhanced by Generative AI and targeted at the technology transfer market.

Internet giants Google and Yahoo were founded following technology transfer by research institutions, while the mRNA vaccine was made possible following university research.

These are just a few examples of the commercial success of technology transfer. GenIP is helping Technology Transfer Offices ensure more such discoveries reach their full market potential.

GL. I see a re-rate is imminent

Now we wait. Bottom drawer minnow. 18% up and climbing 👍

..

TY. Appreciated 👍

I'll be taking a few when listed!!

I see it as incredibly POSITIVE!! Yet ANOTHER step in the right direction! Well done Hemo, and well done us LTHs . Patience will reward!!

..

Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical company developing innovative therapies for blood diseases, is pleased to announce the successful completion of the Site Initiation Visit at the first clinical site for its Phase I clinical trial of HG-CT-1 (also known as HEMO-CAR-T). The Phase I clinical trial is designed as a dose escalation study to assess the safety of HG-CT-1 in adult patients with relapsed/refractory (R/R) acute myeloid leukaemia (AML).

Patient recruitment will begin once the clinical site provides final details to the Company's clinical trials manager, Prevail Infoworks.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "This step marks a significant milestone for the Company as we advance our lead asset, HG-CT-1, into clinical trials. This study represents our commitment to developing innovative therapies for patients with R/R AML, a condition with limited treatment options.

We are excited to see patient recruitment set to begin and take the next steps in assessing the safety and treatment potential of HEMO-CAR-T. We remain dedicated to delivering transformative therapies that address critical unmet medical needs."

RNS out...

Spotted this minnow on X. Which has led me down the AI rabbit holes. Researching some more, and may very well throw a few bob at it. 👍

I have about 4 holdings with decent money invested. Unfortunately, call in a pesky deficit. However, I still believe patience will put right to that, including ORCP and ROCK. I've read and researched till my eyes are sore, so yes, happy to wait for the rewards. Gets a little stomach churning to see such drops mind. Elated when they WHOOSH north lol

Thanks again for your insightful thoughts. Are you still holding/ in favour of ORCP? Your thoughts wld be appreciated 👍

..

I see...